Overview
- Adjusted EPS came in at $0.51 for the quarter, missing the $0.55 consensus.
- Net sales rose 16.6% to $648.2 million, driven by roughly 19.2% volume growth and a 2.6% negative price/mix; Premier Protein net sales increased 14.9% and Dymatize jumped 32.9%.
- Adjusted gross profit declined to $192.4 million and gross margin fell to 29.7% from 35.9% a year earlier.
- Operating profit decreased 8.8% to $102.2 million, while adjusted EBITDA edged up 0.8% to $117.4 million.
- The company guided 2026 sales to $2.410–$2.490 billion below the $2.509 billion Street view, trimmed long-term net sales growth to 7–9% and reaffirmed an 18–20% adjusted EBITDA margin target; management described the protein category as more competitive and the stock was last down about 3.8% to $24.64.